Volume 7.15 | Apr 19

Hematopoiesis News 7.15 April 19, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Age-Dependent Modulation of Vascular Niches for Hematopoietic Stem Cells
Investigators showed that Notch signaling in endothelial cells leads to the expansion of hematopoietic stem cell niches in bone, which involves increases in CD31-positive capillaries and platelet-derived growth factor receptor-β-positive perivascular cells, arteriole formation and elevated levels of cellular stem cell factor. [Nature] Abstract
Register Now for our Live Webinar- Anticipating Cytopenia: In Vitro Methods for Assessing Hematotoxicity
PUBLICATIONS (Ranked by impact factor of the journal)
Distinct Bone Marrow Blood Vessels Differentially Regulate Hematopoiesis
Scientists found that mammalian bone marrow stem cell maintenance and leukocyte trafficking are regulated by distinct blood vessel types with different permeability properties. [Nature] Abstract

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-Like Trials in Mice
Researchers established a large, publicly available repository of well-characterized leukemia and lymphoma patient-derived xenografts that undergo orthotopic engraftment, called the Public Repository of Xenografts. [Cancer Cell] Abstract | Press Release

Runx1 Downregulates Stem Cell/Megakaryocytic Transcription Programs that Support Niche Interactions
The authors investigated the myeloid progenitor (MP) compartment in Runx1 knockout (KO) mice, arguing that disruptions at the hematopoietic stem and multipotent progenitor cell level may be amplified in downstream cells. They demonstrated that the MP compartment is increased by >5-fold in Runx1 KO mice, with a prominent skewing towards megakaryocyte progenitors. [Blood] Abstract

Loss of Ezh2 Cooperates with Jak2V617F in the Development of Myelofibrosis in a Mouse Model of Myeloproliferative Neoplasm
To determine the effects of concomitant loss of EZH2 and JAK2V617F mutation in hematopoiesis, researchers generated Ezh2-deficient Jak2V617F-expressing mice. [Blood] Abstract

P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART
Investigators used an in vitro system to analyze the T- and B-cell potential of CD34+ hematopoietic progenitor cells. Comparisons of immunological nonresponders (INRs) with matched HIV+ patients with high CD4+ T-cell counts (immune responders) revealed an impairment of the generation of T-cell progenitors, but not of B-cell progenitors, in INRs. [PLoS Pathog] Full Article

Evidence that Hematopoietic Stem Cell Function Is Preserved during Aging in Long-Lived S6K1 Mutant Mice
Scientists showed, using gene expression analyses, that there was a reduction in expression of cell cycle genes in young and aged S6 kinase 1 (S6K1-/-) bone marrow-derived c-Kit+ cells when compared to age-matched wild type mice, suggesting that these cells are more quiescent in S6K1-/- mice. [Oncotarget] Full Article

Expansion and Hepatic Differentiation of Adult Blood-Derived CD34+ Progenitor Cells and Promotion of Liver Regeneration after Acute Injury
Researchers report a new group of blood-derived CD34+ progenitor cells that have the ability to expand and differentiate into functional hepatocyte-like cells and promote liver regeneration. [Stem Cells Transl Med] Abstract | Full Article

Spleen Hypoplasia Leads to Abnormal Stress Hematopoiesis in Mice with Loss of Pbx Homeoproteins in Splenic Mesenchyme
Investigators explored the effects that genetic perturbation of the splenic mesenchymal niche has on hematopoiesis upon loss of members of the Pbx family of homeoproteins. [J Anat] Abstract


Clinical Activity of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Investigators studied the tolerability and activity of azacitidine in 181 patients who relapsed after an allograft for acute myeloid leukemia or myelodysplasia. [Haematologica] Abstract | Full Article

Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients with Hematopoietic Stem Cell Transplantation
Investigators evaluated the pharmacokinetic variations of mycophenolic acid, the active metabolite of mycophenolate mofetil, in both pediatric and adult patients following hematopoietic stem cell transplantation. [J Clin Pharmacol] Abstract

Enter for a chance to win ISSCR 2016 Travel Support Award to San Francisco!
Microenvironmental Regulation of Hematopoietic Stem Cells and Its Implications in Leukemogenesis
Hematopoietic stem cells (HSCs) exist alongside several cell types in the bone marrow microenvironment that comprise the stem cell niche. These cells regulate HSC function and can contribute to leukemogenesis. The authors discuss recent advances in this field. [Curr Opin Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
Antibody Therapy Reduces Cancer Stem Cells in Multiple Myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists. [Press release from The Johns Hopkins University discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

New Biomarker Data to Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-Dose IL-2 Immunotherapy, including Those over 60 Years of Age
Scientists from Gothenburg University, Sweden will report data on an immune mechanism-based biomarker to predict the potential efficacy of treatment with Ceplene® in the difficult-to-treat above 60 year old population with AML. [Press release from Immune Pharmaceuticals Inc. discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release | Poster

From our sponsor:
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols.
Watch the video.
Pluristem Continues to Strengthen Its Position in Japan – Granted Two Key Cell Therapy Patents
Pluristem Therapeutics Inc. announced that the Japan Patent Office has granted the company two key patents addressing Pluristem’s core technology of three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells and the use of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system, such as disorders caused by exposure to radiation or chemotherapy, and failed engraftment of hematopoietic stem cell transplants. [Pluristem Therapeutics Inc.] Press Release

TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States
TG Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued a patent for the composition of matter of TG-1101, the company’s novel, glycoengineered monoclonal antibody. The patent, U.S. Patent No. 9,234,045 specifically covers the composition of TG-1101, and its use for treating various forms of CD20 expressing leukemia and lymphoma, including chronic lymphocytic leukemia and various types of non-Hodgkin’s lymphoma, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. [TG Therapeutics, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 21st European Hematology Association Congress
June 9-12, 2016
Copenhagen, Denmark

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Full Member Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Research Associate – Epigenetic Mechanisms of Myeloproliferative Neoplasms and Myeloid Leukemia (State University of New York)

Scientist – Hematology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Engineering Project Lead (Cytonome)

Postdoctoral Fellow – Hematopoietic and Leukemic Stem Cells (The Francis Crick Institute)

Postdoctoral Scientist – Hematological Malignancies (Max Delbruck Center for Molecular Medicine in the Helmholtz Association)

Postdoctoral Fellow – Molecular and Cellular Basis of Hematopoiesis (University of Cincinnati)

Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow Positions – Leukemogenesis (The University of Alabama)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us